Commitments and Contingencies (Details Narrative) - USD ($)			1 Months Ended	12 Months Ended
	Apr. 30, 2016	Feb. 29, 2016	Apr. 30, 2017	Dec. 31, 2017
Issuance of common stock, shares	47,468	20,548	6,928
Accrued expenses				$ 250,000
Pharmaceutical Development Agreement [Member]
Commitments, description				The Amendment, we and Windlas agreed to amend the Development Agreement to reflect our agreement to issue to Windlas, and Windlas’ agreement to accept from us, in lieu of cash payments with respect to forty percent (40%) of the total amount reflected on invoices sent from time to time by Windlas to us, shares of our common stock having an aggregate value equal to forty percent (40%) of such invoiced amount (with the remaining portion of the invoiced amount being paid in cash).
Cash payments percentage				40.00%
Pharmaceutical Development Agreement [Member] | Maximum [Member]
Issuance of common stock, shares				2,000,000